Smoothened Homolog (Protein Gx or SMO) – Pipeline Review, H2 Market Research and Industry Analysis Report 2017

Market Research Hub (MRH) has recently publicized a new study to its vast repository, which is titled as “Smoothened Homolog (Protein Gx or SMO) – Pipeline Review, H2 2017”. Smoothened Homolog (Protein Gx or SMO) – Smoothened homolog (SMO) is a G protein-coupled receptor that probably associates with the patched protein (PTCH) to transduce the hedgehog’s proteins signal. Binding of sonic hedgehog (SHH) to its receptor is thought to prevent normal inhibition by patched of smoothened (SMO). It is required for the accumulation of KIF7 and GLI3 in the cilia.

Request For Sample Report@ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1256886

Smoothened Homolog (Protein Gx or SMO) pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II and Preclinical stages are 6 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Genetic Disorders, Gastrointestinal, Respiratory and Undisclosed which include indications Basal Cell Carcinoma (Basal Cell Epithelioma), Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Gorlin Syndrome (Basal Cell Nevus Syndrome), Medulloblastoma, Cirrhosis, Esophageal Cancer, Idiopathic Pulmonary Fibrosis, Leukemias, Meningioma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Hepatocellular Carcinoma (HCC), Myelodysplastic Syndrome, Peritoneal Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma and Small-Cell Lung Cancer.

The latest report Smoothened Homolog (Protein Gx or SMO) – Pipeline Review, H2 2017, outlays comprehensive information on the Smoothened Homolog (Protein Gx or SMO) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Smoothened Homolog (Protein Gx or SMO) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape for Smoothened Homolog (Protein Gx or SMO)
– The report reviews Smoothened Homolog (Protein Gx or SMO) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in Smoothened Homolog (Protein Gx or SMO) targeted therapeutics and enlists all their major and minor projects
– The report assesses Smoothened Homolog (Protein Gx or SMO) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news and deals related to Smoothened Homolog (Protein Gx or SMO) targeted therapeutics

Reasons to buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand the targeted therapy areas and indications for Smoothened Homolog (Protein Gx or SMO)
– Identify the use of drugs for target identification and drug repurposing
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Smoothened Homolog (Protein Gx or SMO) development landscape
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Smoothened Homolog (Protein Gx or SMO) – Overview
Smoothened Homolog (Protein Gx or SMO) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Smoothened Homolog (Protein Gx or SMO) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Smoothened Homolog (Protein Gx or SMO) – Companies Involved in Therapeutics Development
BeiGene Ltd
F. Hoffmann-La Roche Ltd
Ignyta Inc
IMPACT Therapeutics Inc
Mayne Pharma Group Ltd
Pfizer Inc
Redx Pharma Plc
Sun Pharma Advanced Research Company Ltd
Smoothened Homolog (Protein Gx or SMO) – Drug Profiles
glasdegib – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSA-10 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMP-5471 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
itraconazole – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
patidegib hydrochloride – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RDX-001 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Smoothened (Smo) Receptor for Oncology – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Smoothened Homolog for Oncology – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sonidegib phosphate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
taladegib – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vismodegib – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Smoothened Homolog (Protein Gx or SMO) – Dormant Products
Smoothened Homolog (Protein Gx or SMO) – Discontinued Products

Browse Full Report With TOC@ http://www.marketresearchhub.com/report/smoothened-homolog-protein-gx-or-smo-pipeline-review-h2-2017-report.html

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact–

90 State Street,

Albany, NY 12207,

United States

Toll Free: 866-997-4948 (US-Canada)

Tel: +1-518-621-2074

Email: press@marketresearchhub.com

Website: http://www.marketresearchhub.com/

Designed by CyFocus.com
Powered by CyFocus.net